Status:
RECRUITING
Amino Acid PET-based Response Assessment in IDH-mutant Gliomas (APPEAR)
Lead Sponsor:
LMU Klinikum
Collaborating Sponsors:
Servier Affaires Médicales
Servier Deutschland GmbH
Conditions:
IDH-mutant Glioma (Oligodendroglioma, Astrocytoma)
Eligibility:
All Genders
18+ years
Brief Summary
Background: The radiological follow-up of diffuse gliomas is challenged by the difficult distinction of true progression from treatment-related changes. To this end, the Response Assessment in Neuro-O...
Eligibility Criteria
Inclusion
- ≥ 18 years
- Histologically verified diffuse IDH-mutant glioma (astrocytoma, oligodendroglioma) of any grade as defined in the WHO classification of tumors of the central nervous system
- Postoperative treatment according to current standard of care at the time of study inclusion
- Performance of amino acid PET as part of clinical routine
Exclusion
- Inclusion in another clinical trial/investigational study involving an experimental therapy or study medication
- Inclusion criteria not met
Key Trial Info
Start Date :
July 17 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 16 2030
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07159607
Start Date
July 17 2025
End Date
July 16 2030
Last Update
September 8 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna
Vienna, Austria, 1090
2
LMU Hospital
Munich, Bavaria, Germany, 81377